Finally, MOR202 and TAK-079 anti-CD38 antibodies are actually in phase I/II clinical trials in relapsed/refractory MM patients (ClinicalTrials.gov Identifier: NCT01421186 and NCT03439280, respectively). This evidence concerns the gene CD38 and Miyoshi myopathy.